Dual-function polypeptide having effects of reducing blood sugar and regulating immunity and use of dual-function polypeptide

An immunomodulatory and hypoglycemic polypeptide technology, applied in the field of biochemical pharmacy, can solve the problem of inability to promote the proliferation of pancreatic β cells, and achieve the effects of inhibiting immune attack, inhibiting eating, and reducing glycosylated hemoglobin

Inactive Publication Date: 2019-07-05
NANJING ZERO TO ONE BIOTECH CO LTD
View PDF6 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The biggest bottleneck in its clinical treatment is the inability to promote the proliferation of islet β cells while eliminating the immune attack on β cells caused by autoreactive T cells

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Dual-function polypeptide having effects of reducing blood sugar and regulating immunity and use of dual-function polypeptide
  • Dual-function polypeptide having effects of reducing blood sugar and regulating immunity and use of dual-function polypeptide
  • Dual-function polypeptide having effects of reducing blood sugar and regulating immunity and use of dual-function polypeptide

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0112] Embodiment 1: the drug efficacy comparison of polypeptide Progly-VP of the present invention and Progly peptide, VP peptide

[0113] (1) The fusion of hypoglycemic peptides and immunomodulatory peptides has directionality

[0114] Eight-week-old male C57BL / 6 mice were randomly divided into 3 groups, 10 mice in each group, which were solvent control group (negative control Vehicle group), Progly-VP group, and VP-Progly group for glucose tolerance test. The result is as figure 1 As shown in A, compared with the control group, the Progly-VP group can significantly reduce the blood glucose level. figure 1 B shows that the area under the curve of the Progly-VP group is also significantly lower than that of the control group, and when VP-Progly is linked in this way, the drug effect is reduced, indicating that the fusion of the hypoglycemic peptide and the immunomodulatory peptide has directionality.

[0115] (2) The dual functions of hypoglycemic and immune regulation depe...

Embodiment 2

[0154] Example 2: Comparison of the efficacy of polypeptide P8-VP of the present invention with P8 peptide and VP peptide

[0155] (1) The fusion of hypoglycemic peptides and immunomodulatory peptides has directionality

[0156] Eight-week-old male C57BL / 6 mice were randomly divided into 3 groups, 10 mice in each group, which were solvent control group (negative control Vehicle group), P8-VP group, and VP-P8 group for glucose tolerance test. The result is as Figure 13 As shown in A, compared with the control group, the P8-VP group can significantly reduce the blood glucose level. Figure 13 B shows that the area under the curve of the P8-VP group is also significantly lower than that of the control group, and when VP-P8 is linked in this way, the drug effect is reduced, indicating that the fusion of the hypoglycemic peptide and the immunomodulatory peptide has directionality.

[0157] (2) The dual functions of hypoglycemic and immune regulation depend on the fusion of these...

Embodiment 3

[0196] Example 3: Comparison of the efficacy of polypeptide Progly-P20 of the present invention with Progly peptide and P20 peptide

[0197] (1) The fusion of hypoglycemic peptides and immunomodulatory peptides has directionality

[0198] Eight-week-old male C57BL / 6 mice were randomly divided into 3 groups, 10 mice in each group, which were solvent control group (negative control Vehicle group), Progly-P20 group, and P20-Progly group for glucose tolerance test. The result is as Figure 25 As shown in A, compared with the control group, the Progly-P20 group can significantly reduce the blood glucose level. Figure 25 B shows that the area under the curve of the Progly-P20 group is also significantly lower than that of the control group, and when the P20-Progly is linked in this way, the drug effect is reduced, indicating that the fusion of the hypoglycemic peptide and the immunomodulatory peptide has directionality.

[0199] (2) The dual functions of hypoglycemic and immune r...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to dual-function polypeptide having effects of reducing blood sugar and regulating immunity and the use of the dual-function polypeptide, and belongs to the technical field of biochemical pharmacy. The dual-function polypeptide is combined polypeptide of blood sugar reducing polypeptide and immunity regulating polypeptide, and flexible connecting peptide is arranged or is notarranged between the blood sugar reducing peptide and the immunity regulating peptide. The dual-function polypeptide having effects of reducing blood sugar and regulating immunity has the function ofa GLP-1 analog, promotes proliferation of pancreatic beta cells, reduces the blood sugar of a patient suffering from type I diabetes and reduces saccharification hemochrome, reduces blood sugar of apatient suffering from type II diabetes, restrains feeding and reduces saccharification hemochrome, also has the functions of immunity regulating peptide of autologous antigen of the type I diabetes,regulates immunity, and restrains pathological immunity attack.

Description

technical field [0001] The invention relates to a bifunctional polypeptide with hypoglycemic and immunoregulatory effects and its use, belonging to the technical field of biochemical pharmacy. Background technique [0002] As far as the inventors know, type 1 diabetes (T1DM) is a disease in which pancreatic beta cells are destroyed by autoimmune attack and lead to absolute insulin deficiency. At present, the research on type 1 diabetes is mainly divided into the early stage of diagnosis and prevention, and the middle and late stages of treatment. Among them, diagnosis and prevention mainly focus on the pathogenesis of type 1 diabetes and study the corresponding diagnostic methods and preventive measures. The pathogenesis of type 1 diabetes involves a T-cell-mediated autoimmune attack and, in susceptible individuals, B lymphocytes that produce antibody responses against β-cells, so patients have a long period of time before the onset of clinical symptoms. The autoimmune res...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K19/00A61K38/26A61P3/10A61P37/02
CPCC07K14/605C07K14/47C07K2319/00A61K38/00A61K38/26A61K39/35A61P3/10A61P37/02C07K19/00
Inventor 金亮吕炜锋
Owner NANJING ZERO TO ONE BIOTECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap